CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
Pembrolizumab +1 morebiological
Likely dose
Pembrolizumab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03267888
NCT03267888Phase 2Completed
CompareCT.gov

Pilot Study of Pembrolizumab and Single-Fraction, Low-Dose, Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma

Emory University·interventional·Posted Aug 30, 2017·Updated Sep 4, 2024

In Brief

A Phase 2 clinical trial evaluating Pembrolizumab and Radiation Therapy for ISS Stage I Plasma Cell Myeloma and 4 related conditions. Completed, enrolled 25 participants across 1 site.

Detailed Summary

This pilot clinical trial studies the side effects of pembrolizumab and radiation therapy in treating patients with stage I-III multiple myeloma that has come back after a period of improvement or that does not respond to treatment. Monoclonal antibodies, such as pembrolizumab, may block cancer growth in different ways by targeting certain cells. Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. Giving pembrolizumab and radiation therapy may work better in treating patients with stage I-III multiple myeloma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsISS Stage I Plasma Cell Myeloma, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC, National Cancer Institute (NCI), National Institutes of Health (NIH)

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedAug 30, 2017
Enrollment StartMay 29, 2018
Primary CompletionSep 2, 2022
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 8.8 years ago

Interventions

Pembrolizumabbiological

Given 200 mg IV.

Radiation Therapyradiation

Patients will receive radiotherapy (8 Gy/1 fx) to an extra-osseous site and/or any bony site containing myeloma deposit.